Therapy-related acute myelogenous leukemia and myelodysplastic syndrome
- 109 Downloads
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/MDS) are increasing in prevalence with aging of the population and improved survival of patients treated with chemotherapy or radiotherapy for other malignancies. Research focused on the pathogenesis of t-AML/MDS will provide insight into the pathogenesis of de novo AML/MDS. Participation in clinical trials should be encouraged for this patient population because results with available treatment options are clearly suboptimal.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Mauritzson N, Albin M, Rylander L, et al.: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002, 16:2366–2378.PubMedCrossRefGoogle Scholar
- 6.Oosterveld M, Muus P, Suciu S, et al.: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia, two parallel studies adjusted for various prognostic factors. Leukemia 2002, 16:1615–1621.PubMedCrossRefGoogle Scholar
- 21.Gilliland DG, Jordan CT, Felix CA: The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004, 80–97.Google Scholar
- 26.Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J: Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001, 31:33–41.PubMedCrossRefGoogle Scholar
- 27.Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001, 19:1405–1413.PubMedGoogle Scholar
- 30.Fern L, Pallis M, Ian CG, Seedhouse C, et al.: Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway, possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004, 126:63–71.PubMedCrossRefGoogle Scholar
- 33.Gardin C, Chaibi P, de Revel T, et al.: Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Reflexion en Hematologie. Leukemia 1997, 11:16–21.PubMedCrossRefGoogle Scholar
- 34.Oosterveld M, Suciu S, Verhoef G, et al.: The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 2003, 17:859–868.PubMedCrossRefGoogle Scholar
- 39.Schnittger S, Bacher U, Haferlach C, et al.: Rare CBFBMYH11 fusion transcripts in AML with inv(16)/t(16,16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia 2007, 21:725–731.PubMedGoogle Scholar
- 40.Pedersen-Bjergaard J, Philip P, Larsen SO, et al.: Therapy-related myelodysplasia and acute myeloid leukemia: cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993, 7:1975–1986.PubMedGoogle Scholar
- 44.Lenz G, Dreyling M, Schiegnitz E, et al.: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004, 22:4926–4933.PubMedCrossRefGoogle Scholar